Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to assess strategies for ischemic syndromes (OASIS-2) study

Circulation

Volumn 103, Issue 5, 2001, Pages 643-650

  Eikelboom, John W ^a   Anand, Sonia S ^a   Mehta, Shamir R ^a   Weitz, Jeffrey I ^a   Yi, Cheelong ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angina; Heparin; Hirudin; Myocardial infarction; Platelets

Indexed keywords

HEPARIN; HIRUDIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035814770     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.5.643     Document Type: Article

References (13)

1. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial
2. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization: Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
3. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction: The Thrombolysis and Angioplasty in Myocardial Infarction Study Group
4. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndromes: The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial experience
5. Occurrence and clinical significance of psuedothrombocytopenia during abciximab therapy
6. Heparin-induced thrombocytopenia: Towards consensus
7. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
8. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
9. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
10. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
11. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
12. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
13. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators